Neural Analytics Inc., a medical robotics company developing and commercializing technologies to measure and track brain health, has announced the first site initiation and first subjects enrolled into the CODEX Study, a prospective, single arm multi-center safety and technical feasibility study utilizing an investigational iteration of the Lucid Robotic System (Lucid M1 Transcranial Doppler Ultrasound System and NeuralBot System), at the Ochsner Clinical Foundation in New Orleans, La.
“There is a growing interest in the diagnostic potential of measuring the dynamic changes of cerebral blood flow in different neurological conditions. Participating in the CODEX Study using the Lucid Robotic System to offer an autonomous measurement of cerebral blood flow velocities has been exciting. We look forward to advancing the field and expanding the clinical relevance of non-invasive measurement of cerebral blood flow in neurological conditions,” said Ifeanyi Iwuchukwu, M.D., assistant professor of Neurocritical Care and Stroke at The Ochsner Clinical Foundation.
Dr. Iwuchukwu and the Ochsner Clinical Foundation are the first to enroll subjects into the global multi-center study. Although the Lucid Robotic System is a CE-Marked and U.S. Food and Drug Administration-cleared device, the primary objective of the CODEX Study is to employ an investigational iteration of the Lucid Robotic System to gather and further explore the technical feasibility of the technology in a wider range of patients and neurological pathologies where the monitoring of cerebral blood flow velocities (CBFV) would be of benefit.
“We are pleased and privileged that we are able to partner with Dr. Iwuchukwu and the Ochsner Clinical Foundation in the enrollment of our first patients into the CODEX Study,” said Robert Hamilton, Ph.D., co-founder and chief science officer of Neural Analytics. “This is a big milestone for us, as we are committed to advancing brain healthcare through transformative technology that empowers clinicians with the critical information needed to make clinical decisions and improve patient outcomes.”